Greenwich LifeSciences (NASDAQ: GLSI)

Greenwich LifeSciences: Phase 3 Targeting Recurrent Breast Cancer

Greenwich LifeSciences (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. In a prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites) Phase IIb clinical trial led by MD Anderson, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up.


TransCode Therapeutics (Nasdaq: RNAZ)

TransCode Therapeutics: Targeting Multiple Metastatic Cancers Using RNA

TransCode Therapeutics (Nasdaq: RNAZ) is developing therapeutic and diagnostic candidates designed to deliver on the promise of RNA in oncology. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas and others.


Bragg Gaming Group (NASDAQ: BRAG)

Bragg Gaming: Cutting-Edge Technology Powering the Global Gaming Industry

Bragg Gaming Group (NASDAQ: BRAG) is a next generation gaming group with cutting-edge technology, leading brands and world-class management expertise, developing into a global gaming force. Formed by a team of gaming industry experts, Bragg's main portfolio asset is ORYX Gaming, an innovative business-to-business gaming technology platform and casino content aggregator.


Medalist Diversified (NASDAQ: MDRR)

Medalist Diversified REIT: Restarted Dividend Payments in Q2 2021

Medalist Diversified REIT (NASDAQ: MDRR) was founded in 2003 as a private equity company specializing in acquiring, owning, and managing commercial real estate in the Southeast. The Company’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns. Medalist utilizes a rigorous, consistent, and replicable process for sourcing and conducting due diligence of acquisitions.



BioVie: Multiple Late-Stage Trials Underway Targeting Significant Unmet Needs

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease.


Lantern Pharma (NASDAQ: LTRN)

Lantern Pharma: Revolutionizing the Future of Oncology with AI and Machine Learning

Lantern Pharma (NASDAQ: LTRN) is a clinical stage oncology-focused company who is harnessing the power of Artificial Intelligence and Genomics to develop precision cancer therapies. By leveraging RADR®, Lantern's proprietary big data engine, more effective cancer treatments can be developed and delivered to the right group of patients at a faster rate and for a fraction of the cost.


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market